Influvak

Roman name

Influvac

Pharmacokinetics

Research pharmacokinetics of the drug Influvak pending.

Farmakodinamika

Postwakcinalny immunity is usually within 14 days after inoculation and continuing up to 1 year.

Indications

Prevention of influenza in adults and children over six months in patients with respiratory diseases, cardiovascular diseases, chronic renal failure, diabetes mellitus, stafilokokkovmi infections, immune deficiency (HIV infection, some malignant diseases of the blood), and in patients receiving immunosuppressants cytostatics, high doses of corticosteroid or suffering from radiation therapy; in children and teenagers (6 months to 18 years) receiving long preparations containing azetilsalicilovu acid, and at high risk of developing Rey Syndrome as a result of influenza infection. Vaccination has people over 60 years of age, regardless of their health status.

Pregnancy and lactation

During pregnancy related to the risk of possible side effects with the risk of contracting influenza and the risk of complications of influenza (experience shows that Influvak ® no tertogennogo or toxicity of a fetus). Perhaps during breastfeeding.

Contraindications

Гиперчувствительност ь to the chicken protein, or to any other component of the preparation, strong temperature or allergic reactions after the last vaccination.

Directory → Immunotropona funds → Vaccines, serums, fagi → Influvak